Velocity Clinical Research Leipzig GmbH
- Address
- lock Available on a paid plan
Respiratory Tract Diseases and Asthma Research
At Velocity Clinical Research Leipzig GmbH, the clinical trial activity is focused on respiratory tract diseases, with a clear emphasis on mild to moderate asthma. The research is centered on evaluating whether new inhaled treatment options perform as effectively as established ones, helping to support better control of everyday asthma symptoms.
- Studies in asthma are examining treatment equivalence to determine whether different inhaler formulations provide comparable benefits for adults with controlled or partly controlled disease.
- The trials are aimed at assessing lung function outcomes, which helps researchers understand how well a therapy supports breathing and symptom management over time.
The site contributes to practical clinical research that may inform future inhaled therapy choices for people living with asthma.
Therapeutic Equivalence Studies in Respiratory Medicine
This research program in Leipzig is also exploring whether two versions of the same asthma treatment can deliver similar clinical effects. The focus is on confirming therapeutic equivalence, an important step in making sure patients receive reliable and effective options for long-term disease control.
- Mild to moderate asthma remains the main condition under study, with attention on patients whose symptoms are already partly controlled or controlled.
- The trials are designed to compare treatment performance in a way that supports effectiveness assessment and confidence in respiratory care.
With a small but focused portfolio of trials, the site is contributing to research that may improve how asthma therapies are evaluated and selected.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Velocity Clinical Research Leipzig GmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azd5004 | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.